EBV (LMP2) Peptide Pool
€340.70*
Description
The EBV (LMP2) Peptide Pool from peptides&elephants is designed for advanced T cell stimulation and epitope mapping in immunological studies of Epstein-Barr virus (EBV, HHV-4). This peptide pool consists of 122 synthetic 15-mer peptides, overlapping by 11 amino acids, and covers the full sequence of the Latent Membrane Protein 2 (LMP2) (UniProt ID: P13285).
LMP2 is a latency-associated antigen commonly expressed in EBV-related malignancies such as nasopharyngeal carcinoma and Hodgkin’s lymphoma. It is a known target of both CD4⁺ and CD8⁺ T cell responses. Each unit of the peptide pool allows for the stimulation of up to 2.5 × 10⁸ peripheral blood mononuclear cells (PBMCs) and is optimized for use in T cell assays, such as ELISpot, intracellular cytokine staining (ICS), and flow cytometry-based functional readouts.
Scientific Background
LMP2 is one of the most clinically relevant antigens for therapeutic EBV vaccine development, particularly in the context of EBV-associated cancers such as nasopharyngeal carcinoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disease (PTLD). Therapeutic vaccine candidates using viral vectors encoding LMP2 have successfully induced virus-specific CD8⁺ T cell responses in early-phase clinical trials. Furthermore, adoptive T cell therapies like posoleucel also target LMP2 alongside other latency proteins such as EBNA1, reinforcing its significance as a conserved and immunodominant antigen.
This peptide pool is an ideal tool for:
- Characterizing patient-specific or vaccine-induced T cell responses
- Ex vivo stimulation of EBV-specific T cells Epitope screening and immune profiling
- Immune monitoring in clinical trials of EBV-targeted vaccines or adoptive T cell therapies
TechData
| Gene: | LMP2 |
| Delivery: | 1-3 days |
| Counterion: | TFA |
| Length: | 497 amino acids |
| No. Peptides: | 122 peptides |
| Amount/Aliquote: | 15 nmol (approx. 25µg)/peptide for stimulation of 2,5 x 108 cells |
| Solubility: | Dissolve in a minimum amount of pure DMSO (40µl) and dilute with water to the desired concentration. Please pay attention that the final concentration of DMSO must be below 1% (v/v) to avoid toxicity in the biological system. |
| Protein: | Latent membrane protein 2 |
| UniProt Id: | P13285 |
| Species: | Epstein-Barr virus (EBV; Human herpesvirus 4) |
| Application: | T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response |
| Indication: | Infectious disease, Cancer, Neuroscience |
Documents
References
Cohen JI. Therapeutic vaccines for herpesviruses. J Clin Invest. 2024 May 1;134(9):e179483. doi: 10.1172/JCI179483.
More EBV LMP peptides
